First City Capital Management Inc. Takes $719,000 Position in AstraZeneca PLC $AZNCF

First City Capital Management Inc. bought a new position in AstraZeneca PLC (OTCMKTS:AZNCF) during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 3,644 shares of the company’s stock, valued at approximately $719,000.

A number of other hedge funds have also made changes to their positions in AZNCF. Hughes Financial Services LLC acquired a new stake in shares of AstraZeneca during the 4th quarter worth about $34,000. Bell Investment Advisors Inc acquired a new position in AstraZeneca in the first quarter valued at about $39,000. Fairscale Capital LLC acquired a new position in AstraZeneca in the fourth quarter valued at about $37,000. Aventus Investment Advisors Inc. bought a new stake in AstraZeneca during the first quarter worth about $46,000. Finally, Mascoma Wealth Management LLC bought a new stake in AstraZeneca during the fourth quarter worth about $46,000. Institutional investors and hedge funds own 40.87% of the company’s stock.

AstraZeneca Price Performance

OTCMKTS AZNCF opened at $187.10 on Wednesday. AstraZeneca PLC has a 1-year low of $122.26 and a 1-year high of $195.00. The company has a 50 day moving average of $187.10 and a 200-day moving average of $186.15.

AstraZeneca Company Profile

AstraZeneca (OTCMKTS:AZNCF) is a global biopharmaceutical company that focuses on the discovery, development, manufacturing and commercialization of prescription medicines. The company’s research and development efforts are concentrated in three main therapeutic areas: oncology; cardiovascular, renal and metabolism; and respiratory, inflammation and autoimmunity. AstraZeneca’s product portfolio includes targeted therapies for lung and breast cancers, novel agents for heart failure and chronic kidney disease, and inhaled treatments for asthma and chronic obstructive pulmonary disease.

The company was formed in 1999 through the merger of Sweden’s Astra AB and the United Kingdom’s Zeneca Group, creating one of the world’s largest pharmaceutical firms.